Disclosed are a method for producing a highly reactive intermediate, which comprises: preparing an electron-accepting active compound (1), preparing a piezoelectric material (3), and applying mechanical strain to the piezoelectric material (3) in the presence of the electron-accepting active compound (1) and the piezoelectric material (3), and subjecting the compound (1) to one-electron reduction to generate a corresponding highly reactive intermediate; a redox reaction method using the method for producing the same; and a method for producing a redox reaction product.

Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.

Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.

The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

Provided in the present invention is a novel diaroyl carbazole compound, used together with a carbazolyl oxime ester photo initiator to show a significant synergistic initiation effect in a photoresist composition; the best sensitising effect is shown when the molar ratio of the diaroyl carbazole compound and the carbazolyl oxime ester photoinitiator is 0.1-1.4

A phase difference plate includes a phase difference plate P1 and a phase difference plate P2. An in-plane slow axis of the phase difference plate P1 is orthogonal to an in-plane slow axis of the phase difference plate P2. The phase difference plate P2 includes a layer of a liquid crystal material oriented in an in-plane direction. An in-plane retardation ReP2(λ) at a wavelength λ nm of the phase difference plate P2 satisfies the following formulae (e1) and (e2): {Re2(400)−Re2(550)}/{Re2(550)−Re2(700)}<2.90 (e1), and Re2(400)/Re2(700)>1.13 (e2). An in-plane retardation ReP1(λ) of the phase difference plate P1 at a wavelength λ nm and the in-plane retardation ReP2(λ) of the phase difference plate P2 at the wavelength λ nm satisfy the following formulae (e4) and (e5): ReP1(550)>ReP2(550) (e4), and ReP1(400)/ReP1(700)<ReP2(400)/ReP2(700) (e5).

A phase difference plate includes a phase difference plate P1 and a phase difference plate P2. An in-plane slow axis of the phase difference plate P1 is orthogonal to an in-plane slow axis of the phase difference plate P2. The phase difference plate P2 includes a layer of a liquid crystal material oriented in an in-plane direction. An in-plane retardation ReP2(λ) at a wavelength λ nm of the phase difference plate P2 satisfies the following formulae (e1) and (e2): {Re2(400)−Re2(550)}/{Re2(550)−Re2(700)}<2.90 (e1), and Re2(400)/Re2(700)>1.13 (e2). An in-plane retardation ReP1(λ) of the phase difference plate P1 at a wavelength λ nm and the in-plane retardation ReP2(λ) of the phase difference plate P2 at the wavelength λ nm satisfy the following formulae (e4) and (e5): ReP1(550)>ReP2(550) (e4), and ReP1(400)/ReP1(700)<ReP2(400)/ReP2(700) (e5).

The present invention relates to a method for detection, identification, and/or quantification of one or more microbes, microbial peptides, or compounds of microbial origin, comprising the steps of: (a). contacting an object, a substance, or a sample with a luminescent conjugated oligothiophene (LCO); (b). detecting at least one signal of the luminescent conjugated oligothiophene (LCO) of a); and (c). based on said at least one detected signal in b), determining the presence, identity, and/or quantity of the one or more microbes, microbial peptides, or compounds of microbial origin on said object or in said sample. The present invention further relates to diagnostics and a method of diagnosis of microbes, microbial peptides, or compounds of microbial origin.